This report provides an update on the information obtained from this joint initiative, provides a baseline benchmark report for the performance of transcatheter aortic valve replacement (TAVR) in the United States, and informs development of global registries (5, 6) . It also facilitates identification of specific items of interest, which can then be selected for more focused statistical assessment to better understand inference and/or causal relationships (7) (8) (9) . In the process of implementation, a data dictionary was developed using standardized definitions (10, 11) and was subsequently refined to include 308 elements, including baseline patient characteristics, outcomes, procedural performance, and device selection. Holmes, Jr. et al.
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The TVT Registry Yearly Outcomes The changes in baseline characteristics over the 2 timeframes were clinically minor, although statistically significant due to the size of the registry. Overall, the mean STS risk score (14) Although there were significant differences over time, these differences were not clinically significant. TAVR ¼ transcatheter aortic valve replacement. 
Holmes, Jr. et al. PROCEDURAL PERFORMANCE. Greater than 90% of cases were performed electively (Table 3) ; the remainder were usually classified as urgent. During the 2 time periods analyzed, the procedure itself was typically performed in a hybrid operating room suite (Online Figure 4) ; only 10% to 13% were performed in a catheterization laboratory. This may change as the technology improves with decreasing catheter sizes and may shift the procedure in the future to more frequent performance in a catheterization laboratory.
The specific mode of anesthesia (Online Figure 5) was typically general, with moderate sedation PROCEDURAL OUTCOME. The success rate with device implantation in the correct anatomic position has been excellent, and most recently was 97.4% (Table 4) .
Using Valve Academic Research Consortium (VARC)-1 criteria, device success was 92.7%, reflecting that the device was in the correct anatomic position, as well as satisfactory intended performance of the valve (10, 11, 16) .
In the most recent experience, about one-third of all patients had a hospital complication. However, procedure-related cardiac complications were uncommon at <2% ( Table 5 ). The most common intraprocedural cardiac complication was the need for a new pacemaker (Figure 7) , which occurred in Holmes, Jr. et al.
The TVT Registry Yearly Outcomes The heart team is mandated to evaluate all patients undergoing transcatheter aortic valve replacement (TAVR). The reason for the indication for TAVR, in terms of patient risk, continues to evolve. Values are %.
TAVR ¼ transcatheter aortic valve replacement.
Holmes, Jr. et al. Overall unadjusted in-hospital mortality ( Figure 10) throughout this time period was <5%. The primary cause of mortality was cardiac, and was not substantially different over the period of observation (Table 6) .
OBSERVATIONS. These benchmark data from the TVT Registry have multiple important messages:
1. TAVR candidates have advanced age and multiple comorbidities, which either make them at high risk for surgical aortic valve replacement or render them inoperable.
2. The patients are highly symptomatic, with symptoms that are often refractory. 
19.2%
The small, but significant, changes in site-read aortic regurgitation posttranscatheter aortic valve replacement (TAVR) may have important implications.
Echo ¼ echocardiography.
The TVT Registry Yearly Outcomes Several important uses of TVT Registry data have occurred or are being planned that will further expand the importance of these updated reports:
1. Development of a TAVR-specific risk prediction algorithm focusing on in-hospital mortality.
Future risk prediction algorithms will look at longer-term mortality, stroke, and other nonfatal outcomes.
2. These data will also be used to evaluate the relationship between volume and outcome for TAVR, which has important implications for continued utilization of the approach. 
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The need for and placement of a new pacemaker or implantable cardioverter-defibrillator (ICD) has probably increased, in part, because of the introduction of new transcatheter aortic valve replacement (TAVR) devices. Afib ¼ atrial fibrillation.
Holmes, Jr. et al. 4.2%
Newer technology, with smaller devices and improved vascular access management techniques, has led to a decreasing incidence of both vascular and bleeding complications. TAVR ¼ transcatheter aortic valve replacement. 
